• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Inventiva .(prom.)-,01 News

    3,025 € -0,82% -0,025 €
    26.04.24 09:20:02 Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2DLV9
    ISIN: FR0013233012
    US-Symbol: IVEVF
    Typ: Aktie

    Inventiva .(prom.)-,01 News

    03.04.24 - GlobeNewswire
    Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
    Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
    28.03.24 - GlobeNewswire
    Inventiva announces the nomination of Andre Turenne as Director
    Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
    27.03.24 - GlobeNewswire
    Inventiva reports its 2023 full-year results
    Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022  Cash and cash equivalents at €26.9 million, short-​term deposits at €0.01 million 1 , and ...
    22.03.24 - GlobeNewswire
    Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
    Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
    18.03.24 - GlobeNewswire
    Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
    LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. ...
    13.03.24 - GlobeNewswire
    Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
    Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
    07.03.24 - GlobeNewswire
    Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
    Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. ...
    15.02.24 - GlobeNewswire
    Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
    Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-​term deposits at € 0.01 million 2 , and long-term ...
    24.01.24 - GlobeNewswire
    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
    Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
    10.01.24 - GlobeNewswire
    Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
    Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH. This second tranche carries an ...
    20.12.23 - GlobeNewswire
    Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
    The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.  With this milestone payment ...
    04.12.23 - GlobeNewswire
    Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
    The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-​planned review of safety data The safety assessment was based on the ...
    21.11.23 - GlobeNewswire
    Inventiva reports 2023 Third Quarter Financial Information¹
    Cash and cash equivalents at €43.8 million, short-​term deposits at €0.03 million 2 , and long-term deposit at €5.0 million 3 as of September 30, 2023, compared to €86.7 million, €1.0 ...
    06.11.23 - GlobeNewswire
    Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  
    The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional scientific abstracts from the NATIVE ...
    28.09.23 - GlobeNewswire
    Inventiva reports its 2023 first-half financial results and provides a corporate update
    Cash and cash equivalents at €31.2 million, short-​term deposits at €0.05 million 1 , and long-term deposit at €9.3 million 2 , as of June 30, 2023, compared to €86.7 million, €1.0 million ...
    20.09.23 - GlobeNewswire
    Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
    Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position.   Under the exclusive licensing agreement, Inventiva will ...
    31.08.23 - GlobeNewswire
    Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
    Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-​stage biopharmaceutical company ...
    27.07.23 - GlobeNewswire
    Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
    Cash and cash equivalents at €31.2 million, short-​term deposits at €0.05 million 2 , and long-term deposit at €9.3 million 3 as of June 30, 2023, compared to €86.7 million, €1.0 million ...
    24.06.23 - GlobeNewswire
    Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
    Daix (France), Long Island City (New York, United States) , June 2 4 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
    13.06.23 - GlobeNewswire
    Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
    Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy ( 1 H-MRS) ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »